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Abstract
AGel amyloidosis is a genetic degenerative disease characterized by the deposition of insoluble gelsolin protein aggregates in
different tissues. Until recently, this disease was associated with two mutations of a single residue (Asp187 to Asn/Tyr) in the
second domain of the protein. The general opinion is that pathogenic variants are not per se amyloidogenic but rather that
the mutations trigger an aberrant proteolytic cascade, which results in the production of aggregation prone fragments. Here,
we report the crystal structure of the second domain of gelsolin carrying the recently identified Gly167Arg mutation. This
mutant dimerizes through a three-dimensional domain swapping mechanism, forming a tight but flexible assembly, which
retains the structural topology of the monomer. To date, such dramatic conformational changes of this type have not been
observed. Structural and biophysical characterizations reveal that the Gly167Arg mutation alone is responsible for the mono-
mer to dimer transition and that, even in the context of the full-length protein, the pathogenic variant is prone to form
dimers. These data suggest that, in addition to the well-known proteolytic-dependent mechanism, an alternative oligomeri-
zation pathway may participate in gelsolin misfolding and aggregation. We propose to integrate this alternative pathway into
the current model of the disease that may also be relevant for other types of AGel amyloidosis, and other related diseases
with similar underlying pathological mechanisms.
Introduction
Gelsolin is the prototype of a large superfamily of proteins,
responsible for the assembly, disassembly and scavenging of
actin filaments by means of its severing and capping activities
(1,2). Gelsolin is organized into six homologous domains (G1–
G6), sharing the same gelsolin-like fold (3). Each of these mod-
ules hosts at least one calcium-binding site and the presence of
calcium induces both subtle local and large global conforma-
tional changes (4–7). Namely, actin-free gelsolin exists in two
functional states: in the absence of calcium, the protein adopts
a compact conformation unable to bind actin (inactive form); at
higher calcium concentrations, the gelsolin structure unwinds
leaving the actin binding surfaces exposed (active form) (8,9).
The active conformation is highly dynamic as most of the inter-
domain contacts are lost and the domains are linked only by
flexible stretches of the polypeptide chain (9). For this reason,
no high-resolution structure of calcium-activated gelsolin has
been reported so far and structural biologists have to mainly
rely on the study of isolated domains to gain insight into gelso-
lin physiopathology (3,4,6). In each domain, calcium has a
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structural role and its binding leads to the stabilization of the
gelsolin-like fold and consequently, to decreased conforma-
tional flexibility, which is somehow in contrast to the effect of
calcium on the full-length protein (5,6).
Owing to its pivotal physiological activities and its ubiqui-
tous nature, gelsolin, both in the intracellular and extracellular
form, plays a major role in a plethora of physiological processes,
such as cell motility and cell division, organelle trafficking and
muscle contraction (10). Increasing evidence suggests that
intracellular gelsolin exerts a central role in cell metabolism
and signaling through an actin-independent mechanism (11).
Alteration in gelsolin expression levels or deregulation of its
activities have been observed in several pathological conditions,
including cardiovascular diseases, muscle necrosis, acute respi-
ratory distress syndrome and in particular, cancer (12).
However, a clear relationship between the gelsolin levels and its
effect in protecting or inducing a specific pathological condition
remains to be elucidated. Conversely, the presence of mutations
in plasma gelsolin is known to be directly related to a rare form
of amyloidosis, hereafter referred as AGel amyloidosis (AGel,
OMIM reference number 105120).
Amyloidosis-related diseases are degenerative in nature,
with pathogenicity stemming from incorrect protein folding,
which leads to the deposition of insoluble protein aggregates
(amyloids) in various organs and tissues. More than 20 amyloi-
dogenic diseases, including central and systemic forms, have
been identified. They can be either hereditary, owing to muta-
tion(s) or deletion(s) in the etiological protein, or sporadic, i.e.
associated with external factors.
The first genetic form of AGel, which until recently was the
only one described, was originally known as familial amyloido-
sis, Meretoja’ syndrome or Finnish-type, owing to the clinician
who first described the disease and the country where the path-
ology is endemic, respectively (13). Finnish AGel is caused by
the substitution of Asp187 to either Asn or Tyr (numbering
according to the mature plasma protein or G640 to A or T in the
mRNA sequence) (14,15). Systemic amyloidosis is clinically
characterized by the prototypical symptomatic triad associated
with the deposition of gelsolin fibrillar tangles in the eyes, skin,
peripheral and central nerves. Since its discovery in the late 60s,
AGel cases have been described in many other countries [some
recent examples in (16–18)], in kindred lacking Finnish ances-
tors, suggesting that this disease, owing to its neglected state
and complex and variable clinical picture, has often been un/
misdiagnosed.
Two novel pathological variants of gelsolin have recently
been described to be associated with renal amyloidosis contain-
ing the following mutations: Asn184 to Lys and Gly167 to Arg
(C633 to A and G580 to A, respectively) (19–21). In addition, a
sporadic form of AGel with marked wild-type (wt) gelsolin
deposits surrounding a sellar glioma of the hypophysis has also
recently been discovered (22). This finding is particularly rele-
vant since, in several clinical reports of pituicytoma-associated
amyloidosis (23–25), it is the first one in which the etiological
agent, i.e. the main constituent of the aggregates, was identi-
fied. Therefore, AGel can be classified into three different forms
according to the nature of the protein, mutants or wt, in addi-
tion to the organ(s) involved in fibril deposition: (i) systemic (or
Finnish-type), (ii) kidney localized and (iii) sporadic.
All AGel types share the lack of apt pharmacological therapies
that cure the disease, targeting the source of toxicity, rather than
only acting as palliative, symptomatic treatments. However, the
use of nanobodies raised against mutated gelsolin recently
showed great potential as a novel strategy against AGel, both
in vitro and in vivo exploiting adeno-associated viruses (26–28).
Dissection of the molecular bases that lead to wt and mutant gel-
solin misfolding, and knowledge of the mechanisms underlying
each AGel form, are crucial to identify pharmacologically relevant
targets and to develop effective therapeutic strategies.
With the exception of our recent description of the underly-
ing molecular bases of Asn184Lys amyloidosis (29), little is
known about the pathological mechanisms that lead to renal or
sporadic forms. On the contrary, the amyloidogenic pathway of
the systemic Asp187Asn/Tyr variants is relatively well under-
stood. Asp187 is present in a cluster of residues that chelate cal-
cium in the G2 domain (6,30), and its substitution compromises
calcium binding and leads to overall domain destabilization
(31). Such increased flexibility makes the protein susceptible to
aberrant proteolysis, triggered by endogenous furin in the Golgi
(32). The major product of furin activity, the C68 fragment,
becomes a substrate of other enzymes and the proteolytic cas-
cade eventually leads to the production of two aggregation
prone peptides (5 and 8 kDa). Therefore, in Finnish amyloidosis
only the exported isoform of the protein is responsible for the
disease and the full-length mutant protein is not per se amyloi-
dogenic, only the short fragments are found in fibrillar tangles
(33,34). These findings however, are in contrast with laser dis-
section studies, followed by mass spectrometry analysis of
Gly167Arg deposits that identified gelsolin fragments that do
not correspond to the canonical 5 and 8 kDa peptides (19), sug-
gesting that either the full length protein aggregates or this
mutant is characterized by a different proteolytic pattern.
The effect of Gly167Arg substitution in the G2 domain of gel-
solin on the amyloidogenic pathway is investigated here. We
report the first crystal structure of this protein variant and show
that the Gly167Arg mutation promotes gelsolin dimerization via a
peculiar 3D domain swap mechanism. Our results challenge the
current paradigm on gelsolin aggregation and propose an alterna-
tive, proteolysis-independent pathway for the deposition of the
Gly167Arg variant. The domain swap versus proteolysis mecha-
nism may explain the observed differences in fibril localization
and the clinical picture induced by different mutations. Owing to
the generality of the proposed mechanism, our findings may be
relevant to the other AGel forms and to other similar diseases,
whose pathological mechanisms are still under investigation.
Results
The structure of the gelsolin domain 2 Gly167Arg
mutant
Domain swap mechanism
In a previous study, we successfully used a combination of bio-
physical and biochemical approaches to understand the role of
the Asn184Lys mutation in the amyloidogenicity of gelsolin (29).
A similar approach was here applied to dissect the molecular
bases of the pathogenicity of the other variant responsible for
gelsolin-related renal amyloidosis. To this end, we used the G2
domain (amino acids 151–266) carrying the Gly167Arg mutation,
for extensive crystallization trials. Crystals readily grew in 0.2 M
ammonium acetate, 0.1 M sodium citrate, pH 5.6, 30% PEG 4000
and the structure was solved by molecular replacement using the
Asn184Lys variant as a search model (see Table 1 for data collec-
tion and refinement statistics). Contrary to the previously pub-
lished gelsolin G2 crystal structures, two molecules were present
in the asymmetric unit and during refinement we observed a dis-
continuity in the electron density corresponding to a loop con-
necting b-strand b1 to b2 (hereafter named as the hinge loop)
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(Supplementary Material, Fig. S1). Indeed, such discontinuity was
owing to an unusual conformation of the crystallographic dimer,
with the N-terminal b1 strand of each monomer contributed
from the other polypeptide chain (Fig. 1). This rare mode of asso-
ciation is known as 3D domain swapping [reviewed in (35,36)],
whereby secondary structure elements or a structural domain of
one protein is replaced by the same element donated from
another protein. Although domain swapping has already been
associated with both physiological and pathological processes,
our structure is the first example of a gelsolin mutant that adopts
such a conformation. The dimerization interface between the
two monomers mainly involves the swapped b1 strand, compris-
ing residues 158–166, covering a total contact area of 2375 A˚2 (Fig.
2A). In addition, the two stretched hinge loops interact in a
pseudo b-antiparallel fashion, contributing several polar interac-
tions to the assembly (Fig. 2A and E and Table 2). All inter-
domain interactions (more than forty H-bonds) belong to the
interface between the open monomers [O-interface according to
Eisenberg nomenclature (36)] and no contact occurs between the
closed subunits (C-interface).
All attempts to obtain the structure of the mutant in the
monomeric form failed, therefore we compared the Gly167Arg
dimer with the wt G2 structure. If the hinge loop (residues 168–
172) and the C-terminal region of the domain (residues 258–265,
not visible in the mutant structure owing to its flexibility) are
not included in the superposition, the two structures are highly
similar with root mean square deviation (r.m.s.d.) of 0.40 A˚ (over
79 Ca atoms) (Fig. 2B and Table 2).
Analysis of the Gly167Arg mutant provides clear hints about
the structural bases of the dimerization process. In both wt, and
to a great extent in Asn184Lys G2, the hinge loop exhibits some
flexibility (6,29). The loop also displays some turn characteris-
tics, as the residue 166 (n) forms an intramolecular H-bond with
residue 172 (nþ 6), and in position nþ 1 the loop hosts Gly167,
which sits in a peculiar region of the Ramachandran plot, spe-
cifically accessible only to glycine and definitely unfavorable for
other residues (Fig. 2C). Contrary to this, the stretched confor-
mation of the hinge loop adopted in the Gly167Arg dimer better
accommodates the bulky residue, eliminating the torsional
strain. Furthermore, the mutation adds a basic amino acid (Arg)
to the hinge loop, which already hosts three arginines and one
lysine, attributing five positive charges to a short stretch of
seven amino acids (Fig. 2C–E). This is an extremely high concen-
tration of charges that extend over a limited area, which neces-
sarily leads to electrostatic repulsion. Therefore, the Gly167Arg
mutant triggers the conformational change to release both the
torsional strain and the repulsion among the basic residues.
In addition to the described structure, we collected a second
low resolution dataset for the Gly167Arg mutant in a different
space group (P21) and the resulting 3D model was partially refined
to 2.6 A˚ resolution. Also in this crystal, the mutant forms a dimer
stabilized by the same domain swapping mechanism. The rela-
tive orientation of the two subunits differs between the two struc-
tures, both in terms of the angle between the monomers and
rotation along the symmetry axis (Fig. 2G). This evidence suggests
that the mutual orientation of the two monomers in the dimeric
assembly is mostly dictated by crystal packing rather than by
inter-domain interactions, demonstrating the intrinsic flexibility
of the hinge loop.
Calcium-binding site
Although no crystal structure of Asp187Asn/Tyr variants is
available, calcium-binding impairment was reported as the
primary cause of their amyloidogenicity. Solution and computa-
tional studies on these mutants showed that in the absence of
calcium, the C-terminal tail of the protein is highly dynamic
with a tendency to expose the empty calcium-binding cavity (6).
In one of the two structures of the Asn184Lys mutant we
observed similar behavior, although the calcium ion was still
firmly bound (29). Similarly, in the Gly167Arg dimer structure,
we could only model up to residue 257 and 258 in chains A and
B, respectively. The remaining 7/8-residue segment was too
flexible to be modeled, suggesting that destabilization of the C-
terminus of the G2 domain is a feature common to all gelsolin
pathogenic variants described to date (Figs 1 and 2F).
Dimerization itself is partially responsible for this behavior as
the C-terminus would clash against the hinge loop in the con-
formation observed for the wt protein. Surprisingly, neither
dimerization nor destabilization of the C-terminal segment
impair the ability of the mutant to bind calcium. The electron
density for calcium is clearly visible and its occupancy was
refined at 100%. In the other G2 structures, calcium is hexacoor-
dinated by Gly186, Asp187, Glu209 and Asp259, but the last resi-
due is disordered in the Gly167Arg mutant and, in its place, we
observed a citrate molecule in both subunits (Fig. 2F). Citrate
was derived from the crystallization condition (0.1 M concentra-
tion) and was H-bonded to residues 186, 204, 206 and the
mutated 167 residue. Citrate binding does not seem to be the
cause, but a consequence, of the opening of the C-terminus,
since in the Asn184Lys mutant, in the absence of citrate, water
molecules replace Asp259.
Molecular dynamics simulations
As the structure of monomeric Gly167Arg G2 is unavailable, we
performed two molecular dynamics (MD) simulations (80 ns)
using the coordinates of the in silico mutant structure of the wt
G2 domain (pdb-id 1KCQ) in order to analyze the impact of the
mutation on protein dynamics, either in the presence or
absence of calcium.
When G2 is bound to the calcium ion, the Ca r.m.s.d. value
with respect to the initial model is promptly stabilized at 1 A˚
(Supplementary Material, Fig. S2A), and is maintained through-
out the simulations, suggesting that structure stability is kept in
the mutant. During the simulations, the main chain of Arg167 is
constrained in an unfavorable region of the Ramachandran plot
with a Phi of 120625 and a Psi that alternates aroundþ150
and 150 (Supplementary Material, Fig. S2B). Arg167 is main-
tained in this unfavorable conformation by a H-bond formed
between its main chain nitrogen and the side chain of Glu209,
which is in turn bound to the calcium ion. Therefore, from the
MD simulations, even in the presence of the geometric strain
induced by the Gly to Arg mutation, the role of calcium in main-
taining the native-like conformation of the hinge loop clearly
emerges.
On the contrary, simulations performed in the absence of
calcium, showed that the increased motility of the hinge loop
relieves the torsional strain imposed on Arg167. This higher
conformational freedom is also reflected by the overall Ca
r.m.s.d. with respect to the initial structure that continuously
increases during the simulation time (Supplementary Material,
Fig. S2A). Interestingly, without calcium the secondary structure
elements around the hinge loop start to lose their integrity
(Supplementary Material, Fig. S2C versus D), giving the first clue
to a possible domain swapping process.
Despite the short-time range explored in the simulations, all
data indicate the destabilization of the hinge loop induced by
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the mutation, especially in the absence of calcium. Such a fea-
ture is in agreement with our experimental data presented on
the monomer-to-dimer transition (see below).
Kinetics and mechanism of Gly167Arg G2 dimerization
Following the presence of the domain swapped dimer of
Gly167Arg in the crystal, we carried out analytical gel filtration
(GF) experiments to separate the monomeric and dimeric forms.
Indeed, the two oligomeric species could be resolved by analyti-
cal GF, allowing for dimerization studies to be carried out on the
solution. Two possible processes may explain the formation of
the domain swapped dimer: either the dimer is formed directly
during protein folding and thereafter remains stable, or the two
species are in dynamic equilibrium. To test the latter hypothe-
sis, isolated dimers and monomers were incubated under three
different conditions. Time-course transitions in both directions
were analyzed by GF as reported in Figure 3A and B. These anal-
yses revealed that monomer to dimer transitions can occur.
However, at low temperature (4 C), the two isolated conforma-
tions remain well separated over a relatively long time. Both an
increase in temperature (25 C) and/or calcium depletion upon
the addition of ethylenediaminetetraacetic acid (EDTA) promote
the conformational transition toward a mixed population with
some differences in the transition rate and in the final
A
B
C
Figure 1. Gelsolin Gly167Arg domain 2 structure. Cartoon representation of (A) the domain-swapped dimer, (B) the open monomer as extrapolated from the previous
assembly and (C) the closed monomer from the wt structure (PDB id 1KCQ). All structures are viewed in approximately the same orientation; N- and C-termini, the
mutation site, the bound calcium ion and the b-strands are labeled. The hinge loop, which is the region of the protein that links the swapped domains, is also
indicated.
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monomer/dimer ratio. In the tested conditions, irrespective of
whether experiments commenced from monomer or dimers,
the equilibrium values converge to roughly 50%. To further
investigate this aspect, aliquots of Gly167Arg monomer, in a
range of protein concentration between 0.2 and 2 mg/ml, were
incubated for 48 h at 4 C with 1 mM EDTA, and analyzed by GF.
As expected, we found a correlation between the monomer:-
dimer molar ratio and the concentration of total protein (see
Supplementary Material, Fig. S3). Calcium depletion seems to
play a dual role in the dimerization process: (i) it destabilizes
the gelsolin fold and favors protein opening facilitating the
transition; and (ii) it shifts the equilibrium toward dimerization,
lowering the energy associated with this conformation. These
data are in accordance with the MD simulations that showed
that calcium helps to maintain the stressed structure, whereas
the G2 domain (and the hinge loop in particular) promptly starts
to relax in the absence of calcium.
To achieve a more quantitative description of the process,
we studied dimerization by dynamic light scattering (DLS)
under the same conditions used in GF experiments (Fig. 3C). At
4 C, and in the presence of calcium, we confirmed the stability
of the monomer (measured hydrodynamic radius 2.06 0.3 nm).
In the other two conditions (i.e. at 4 C with EDTA and at 25 C
with calcium) the conversion to dimers follows a pseudo-first-
order kinetics (Fig. 3C), with calculated k (t1) values of 2.16 0.2/
h or 0.660.1/h, respectively. Once again, these experiments
suggest that the two species are separated by a high kinetic bar-
rier that can be lowered by removing Ca2þ. When no significant
rearrangement of the backbone is involved, protein–protein
interactions are typically based on rapid association kinetics.
A
C
F G
D E
B
Figure 2. Details and characteristics of the domain-swap dimer. (A) Interactions between Chain A (transparent surface) and swapped strand b1 of Chain B (cyan sticks).
(B) Superposition of wt monomer (yellow cartoons) with chain A of the Gly167Arg dimer (white cartoons). (C) Ramachandran plot for arginines (gray gradient indicates
most favorable angles), the red asterisk shows the position of Arg167 in the dimer (from the reported structure) while the black symbol the corresponding Gly167 in the
wt monomer. (D and E) Zoom view of the hinge loop in a model of the mutant monomer and in the crystal structure of the domain-swapped dimer. Positively charged
residues hosted by the segment are shown as sticks. (F) The calcium-binding site in the Gly167Arg dimer showing the calcium ion (green sphere), chelating residues
(sticks) and Arg167 that forms a H-bond with the citrate molecule (cit., in yellow). All residues are labeled. 2Fo-Fc electron density, contoured at 1.5r, for calcium and
citrate is also visible as a gray grid. (G) Superposition of chain A of the dimer (cyan and white cartoon) with chain A of the lower resolution monoclinic structure (green
and orange), to highlight differences in the relative orientation of the monomers in the two crystals.
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The low rate constants we measured suggest the presence of a
large conformational change supporting the domain-swapping
dimerization process.
In the monomer to dimer conversion, the mutant must nec-
essarily adopt a transition state, where the b1 strand is extruded
from the core of the protein (open monomer) before being
locked again into the other open monomer. To gain insight into
the mechanisms of this process, we produced a truncated form
of the G2 domain (Db1G2) that lacks N-terminal strand b1 (i.e.
starting from residue Arg168). Db1G2 was characterized by GF
and circular dichroism spectroscopy (CD) (Supplementary
Material, Fig. S4). Despite the fact that Db1G2 cannot dimerize
via domain swapping, two peaks were observed in the GF pro-
file: a minor peak eluting at a similar elution volume (VE) to the
folded monomer (VE¼ 13.5 ml) and a major peak with a lower VE
of 12 ml, corresponding to a form with an increased hydrody-
namic radius. CD analysis revealed that Db1G2 lacks any secon-
dary structure elements and its spectrum reflects that of
denatured G2 domains (Supplementary Material, Fig. S4). In
conclusion, the Db1G2 domain behaves as a stable and soluble
protein with random coil or molten globule structural charac-
teristics. Such evidence suggests that domain swapping may be
favored when the protein undergoes partial denaturation, lead-
ing to extrusion of b1. This transition state (open monomer) is
not prone to aggregation or precipitation.
Gly167Arg G2 stability and susceptibility to proteolysis
Several studies report that most monogenic disease mutations
have an impact on protein folding rather than its physiological
function (37). For hereditary amyloidosis, in particular, there is
often a tight correlation between thermodynamic stability of
the mutant protein and its propensity to aggregate. For these
reasons, we analyzed the thermal stability of Gly167Arg by CD
spectroscopy and compared the results with those previously
obtained for other gelsolin variants (Fig. 4 and Table 3).
Experiments were performed in the presence and absence of
calcium to assess both functional states of the protein, and to
verify the ability of the mutants to bind calcium in solution. As
expected, calcium has a stabilizing effect on the G2 domain of
Gly167Arg, with a DTm of 12 C. This difference is comparable
with that observed for Asn184Lys, but is lower than the DTm cal-
culated for the wt, suggesting that the mutations have a lower
impact on the apoprotein fold. Nevertheless, the Tm values for
Gly167Arg in both conditions are at least 10 C lower than those
measured for the wt, implying that the mutation itself increases
the conformational flexibility of the domain.
As previously mentioned, the first step in the amyloidogenic
pathway of the Asp187Asn/Tyr and Asn184Lys mutants, is the
aberrant cleavage of the protein by furin, an endogenous pro-
tease of the Golgi network, primarily involved in the maturation
of exported proteins. We tested the susceptibility of the
Gly167Arg mutant to furin proteolysis in conditions mimicking
the Golgi environment and at two different temperatures (37
and 25 C). Proteolysis of the G2 domain was followed by SDS-
PAGE and analytical GF, with the aim to investigate which oligo-
meric species is most prone to degradation (Fig. 3D and E). By
GF, we can easily distinguish monomers (VE ¼ 13.5 ml), dimers
(VE¼11.2 ml) and the product of furin proteolysis (VE¼12 ml)
(Fig. 3D). The latter has a larger VE with respect to the undi-
gested G2 domain, suggesting that G2 proteolysis leads to its
denaturation (Figs 3D and 4A). Although it is difficult to appreci-
ate subtle differences in our semi-quantitative assays, these
results show that both forms of Gly167Arg are readily processed
by furin and that the extent of their sensitivity is similar or
slightly lower than that of the Asp187Asn mutant, used as a
positive control. The lack of significant differences between
monomers and dimers suggests that either furin processes
monomers and dimers with similar efficiency or that the equili-
brium between the two forms is faster than proteolysis under
our experimental conditions.
Impact of Gly167Arg mutation on the full-length protein
The study of the structure and of the biophysical properties of full-
length gelsolin is challenged by the existence of multiple
Table 1. Data collection and refinement statistics
Data collection
Beamline ID30B (ESRF)
Wavelength (A˚) 1.01
Space group C 1 2 1
Cell dimensions
a, b, c (A˚) 106.3, 44.4, 58.0
a, b, c () 90.0, 110.1, 90.0
Unique reflections 26, 967
Resolution range (A˚) 45.40–1.70(1.74–1.70)a
I/r(I) 9.82 (1.91)a
R-meas (%) 12.4 (80.2)a
Completeness (%) 95.5 (98.5)a
Multiplicity 3.5 (3.5)a
Refinement
Resolution range (A˚) 45.39–1.70(1.77–1.70)a
Rwork/Rfree (%)
b 19.9/24.2(34.9/34.4)a
r.m.s.d.
Bonds (A˚) 0.011
Angles () 1.066
Ramachandran plot
In preferred regions (%) 96.5
In allowed regions (%) 3.5
B-factors (A˚2)c 19.4
Statistics of the domain swapped dimer of the Gly167Arg G2 gelsolin mutant.
Model and structure factors have been deposited in the protein data bank
(http://www.rcsb.org/pdb/home/home.do) under accession code 5O2Z.
aValues in parentheses refer to the highest resolution shells.
bRwork¼RhklkFojjFck/RhkljFoj for all data, except 5%, which were used for calcula-
tion of the Rfree.
cAverage temperature factors for the overall structure.
Table 2. Characteristics of the intertwined assembly
No. of swapped residuesa 9 (158–166)
No. of residues in the hinge loopa 5 (167–171)
No. of intermolecular H-bonds (salt bridges)b 41 (13)
Buried interaction area (A˚2)a,c 2375
Total interaction surface (A˚2)a,b 2987
r.m.s.d. wt monomer versus G167
dimer (Chain A) A˚ (no. of Ca atoms)
0.4 (79)
Physico-chemical parameters of the domain swapped dimer. The table lists
parameters similar to those cited in (36) to compare our structural features with
those of other domain-swap proteins previously characterized.
aValues are intended as ‘per subunit’.
bComputed using the PISA software.
cCalculated by subtracting the solvent accessible surface area of the closed
monomer from that of the open monomer.
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functional states and high conformational flexibility.
Nevertheless, in order to validate our findings on the isolated G2
domain, full-length plasma gelsolin and the Gly167Arg pathologi-
cal mutant were produced. Preliminary spectroscopic analyses
ruled out a major impact of the mutation on the protein structure.
CD spectra of wt and Gly167Arg gelsolin were recorded and pro-
teins were analyzed in temperature ramp experiments under the
same conditions used for the isolated G2 domains. Comparisons
made between the four spectra failed to highlight any major dif-
ferences, suggesting that the mutation does not significantly affect
protein structure or calcium regulation (data not shown). In the
presence of calcium, the temperature ramps are superimposable
(with a characteristic biphasic profile) and calculated Tm values
are within experimental error (Fig. 4 and Table 3). In contrast, sig-
nificant differences are evident in the presence of EDTA, i.e. when
the protein is in a closed conformation (inactive state). Mutant
unfolding still shows high cooperativity, suggesting that the pro-
tein is properly folded but its Tm value is 6 C lower than that
measured for the wt (Fig. 4 and Table 3). GF analysis of the full-
length variants highlighted differences between the wt and the
mutant only for the inactive conformation (in the presence of
EDTA). The Gly167Arg elution profile is characterized by two
peaks: the main one corresponds to the wt protein (VE¼13.5 ml)
and the second to a higher molecular weight protein (VE¼11.7 ml;
Figure 3. Kinetics of dimerization and susceptibility to furin proteolysis. (A and B) The kinetics of dimerization were followed by analytical gel filtration. Curves were
obtained for monomers (A) or dimers (B) under three different conditions: in the presence of calcium at 4 C (filled circle) and 25 C (open square), in the absence of cal-
cium at 4 C (filled square). The fraction of dimers calculated as a fraction of total protein loaded, is plotted as a function of time (h); (C) as for the previous panels, the
monomer to dimer transition was monitored by DLS, data were fitted with a first-order kinetics; (D) gel filtration profile of the Gly167Arg monomer and dimer, in com-
parison with the Asp187Asn variant that does not domain-swap but is susceptible to furin proteolysis. The samples were analyzed at time zero (dotted line) or after
incubation at 25 C for 16 h in the presence (continuous line) and absence (dashed line) of furin. Three elution peaks can be observed corresponding to the dimer
(11.5 ml elution volume, d), monomer (13.5 ml, m) and a larger product of furin proteolysis (12 ml, pp). (E and F) Furin proteolysis assays were performed on Asp187Asn
and Gly167Arg variants at 25 or 37 C and visualized by SDS-PAGE.
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Fig. 5A). Since no high molecular weight bands were visible by
SDS-PAGE analysis (Fig. 5B), the two peaks correspond to different
structural states of gelsolin. This elution profile might be the result
of either the opening of the structure in a calcium-independent
way (i.e. the mutation interferes with the proper regulation mech-
anism) or the formation of dimer/oligomers of the protein. To
answer this question, we incubated wt and Gly167Arg proteins
with bis(sulfosuccinimidyl)suberate (BS3), a crosslinking agent, in
the absence of calcium and analyzed the reaction products by
SDS-PAGE. As can be seen in Figure 5B, the peak eluted in GF with
a VE of 8.7 ml, corresponding to larger oligomeric assemblies of
mutant gelsolin, which is covalently blocked by the crosslinker. To
further investigate the nature of these oligomers we analyzed the
full-length Gly167Arg by multi-angle light scattering (MALS)
coupled with GF. MALS gives a reliable estimation of absolute
molecular weights of macromolecules separated by GF. The light
scattering measure supports the presence of a 77.56 1% kDa mole-
cule, eluting at 13.5 ml, and larger 156.666% kDa species
(VE ¼ 11.7 ml). These values are consistent with the monomeric
and dimeric forms of gelsolin full-length, as the protein theoretical
molecular weight is 83 kDa.
In conclusion, the Gly167Arg mutation promotes gelsolin
dimerization in the full-length protein. Interestingly, these
dimers are only observed in the absence of calcium, when the
conformational stability of the protein is compromised and
when the domain-swapped dimeric conformation is favored.
Discussion
Out of the four gelsolin amyloidogenic mutations identified to
date (http://www.amyloidosismutations.com; date last accessed
23 October 2017), Gly167Arg is the rarest, being found in a single
family. Alternatively, it is the mutation that has eluded current
diagnostic tools the most since diagnosis in the amyloidosis
field is still suboptimal. Compared with other pathogenic var-
iants, Gly167Arg mutation is also less conservative in terms of
physico-chemical properties of the two amino acids. Glycine is
a peculiar residue with enhanced conformational freedom, as
shown by its unique Ramachandran plot. On the contrary, argi-
nine contains a large, bulky guanidinium side-chain that carries
a positive charge under all physiological pHs. Hereditary amy-
loidosis is classified as misfolding diseases and, indeed, muta-
tions are responsible for conformational changes of the native
state of the protein, which eventually lead to the deposition of
ordered protein aggregates. Nevertheless, even in cases where
the mutation drastically changes protein function and behavior,
the impact on the native structure is often subtle and localized,
eluding structure-based mechanistic interpretation (38). In con-
trast, the presence of the Gly167Arg mutation in gelsolin causes
a dramatic reorganization of the polypeptide chain, forming the
domain-swapped dimer.
Domain swapping was first described in 1994 and represents
a peculiar mechanism that forms protein assemblies (39). Since
its discovery, accumulating evidence suggests that domain
swapping-mediated oligomerization is involved in several phys-
iological processes, exploited by nature as a regulatory mecha-
nism (40) and to evolve novel functions (41) in a similar way to
gene duplication. Domain swapping has also been associated
with pathological aggregation of proteins, as in serpinopathies
Figure 4. Impact of the mutation on gelsolin thermodynamic stability. Left panels: thermal denaturation of Gly167Arg (black trace) and wt (grey trace) G2, monitored by
CD spectroscopy, in the absence (top) and presence (bottom) of calcium. Right panels: The same analysis was also performed on the full length proteins.
Table 3. Thermodynamic stability of gelsolin G2 and full-length
G2 Full-length
þCa Ca þCa Ca
WT 60.6a 41.5a 56.7/61.5 56.6
Asp187Asn 46.5a 46.4a nd nd
Asn184Lys 47.0a 33.8a nd nd
Gly167Arg 45.6 33.1 55.5/61.5 51.5
Conformational flexibility was evaluated by CD spectroscopy in the presence of
either 1 mM calcium (þCa) or 1 mM EDTA (Ca). Tm values (6 0.3 C) for the
Gly167Arg mutant are compared with those of the wt protein and other previ-
ously characterized variants. nd, never determined values.
aValues from Ref. (29).
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(42), Alzheimer’s disease (43) and the more related case of cysta-
tin C, whose Leu68Gln mutation is responsible for another
hereditary amyloidosis. Contrary to gelsolin, wt cystatin C
shares the pathological variants ability to dimerize (44).
The gelsolin Gly167Arg mutation plays multiple roles in
AGel. The substitution increases the conformational flexibility
of the G2 domain, which becomes prone to proteolysis by furin.
Aberrant cleavage by furin is the first step in the proteolytic cas-
cade, which leads to the Finnish form of the disease.
Nevertheless, mass spectrometry analysis of Gly167Arg depos-
its identified protein fragments different from the canonical
amyloidogenic stretches (19), suggesting that the full-length
protein may also aggregate via a mechanism that cannot be
explained by the proteolytic pathway alone. The ability of the
mutant to form domain swapped dimers implies the existence
of an alternative, proteolysis-independent mechanism. Furin
requires calcium for activity, therefore the proteolytic pathway
may be referred to as a calcium-dependent mechanism. In con-
trast, the absence of calcium favors dimerization of the protein.
In conclusion, we believe that the current AGel pathological
model should be revised to integrate our findings and to take
into account the coexistence of two parallel amyloidogenic
mechanisms (Fig. 6): the well-known aberrant proteolytic cas-
cade and a calcium-independent pathway that starts with pro-
tein dimerization mediated by domain swapping. There may be
a potential cross-talk between the two proposed pathways, as
full length oligomers may be unable to form amyloids and their
aggregation may be primed by the 5 and 8 kDa fragments.
Another aspect that should be investigated is the origin of the
calcium-free (inactive) protein that undergoes dimerization.
The plasma isoform of gelsolin, responsible for the Finnish
AGel, is believed to be constitutively active, as the concentration
of free calcium throughout the secretory pathway and in the
plasma are sufficient for the activation of the protein.
Conversely, the cytoplasmic isoform of gelsolin could be the
etiological agent of this amyloidosis. Some intracellular prefi-
brillar aggregates of the Gly167Arg variant initially accumulated
in the cytoplasm might be released in the extra cellular space
upon cell death. Release of intracellular amyloids is a mechanism
that has been recently described in some Tau- and a-synuclein-
related diseases, which are now recognized as canonical amy-
loidosis (45,46). In the formulation of these hypotheses, we
should also take into account the kidney-localized deposition of
the Gly167Arg aggregates. Available clinical data are very lim-
ited and we cannot rule out the participation of other external
factors in the disease, which would tag the Gly167Arg substitu-
tion as a risk factor rather than as a disease-causing mutation.
Finally, the calcium-dependent activation of the Gly167Arg
might be altered, although binding of the ion is not completely
impaired. This would lead to the circulation of a small popula-
tion of inactive gelsolin at physiological concentration of cal-
cium, sufficient to produce the first fibrillar seeds.
Currently, the general consensus is that early oligomers and
prefibrillar assemblies of amyloidogenic proteins, rather than
mature fibrils, represent the most relevant species in the path-
way that leads to protein deposition and toxicity (47–50). Our
findings indicate that, in accordance with other protein misfold-
ing diseases, soluble oligomeric structures may be actively
involved in AGel. The identification and characterization of
such structures may significantly contribute to an improved
comprehension regarding the molecular mechanisms of dis-
ease, paving the way for the design of innovative pharmacologi-
cal approaches.
Materials and Methods
Cloning and mutagenesis
Gly167Arg G2 variant (residues 151–266) and the truncated form
Db1G2 (168–266) were produced by site-directed mutagenesis,
using the wt construct (29) as template and the Q5VR Site-Directed
Mutagenesis Kit (New England BioLabs). Primers were designed
using the manufacturer’s software (nebasechanger.neb.com).
The nucleotide sequence encoding for mature human full-
length plasma gelsolin (GSN, residues 26–782, UNIPROT P06396)
was optimized according to E. coli codon usage. The gene was
synthesized by Eurofins Genomics (Ebersberg, Germany) and
cloned into a pET-28a plasmid carrying a 6xHis-tag at the N-ter-
minus of the protein.
Recombinant plasmids (G2_Gly167Arg/pET28, Db1G2/pET28
and GSN/pET28, GSN_Gly167Arg/pET28) were used to transform
either BL21 (DE3) or Rosetta E. coli cells (InvitrogenTM).
Expression and purification
The Gly167Arg G2 mutant and the Db1G2 variant were
expressed and purified following the protocol described in (29)
for the G2s construct.
GSN wt and GSN Gly167Arg were produced in BL21 and Rosetta
(DE3) pLysS??, respectively, and the expression was induced upon
A
B
Figure 5. Oligomerization of the full-length mutant protein. (A) Left axis: analyti-
cal gel filtration elution profile of wt (continuous thin line) and Gly167Arg
(dashed thin line) full length proteins in the absence of calcium. In the presence
of calcium, no significant difference was visible (data not shown). Right axis:
molar mass calculated on-line by MALS for the two peaks of Gly167Arg GSN
(continuous thick lines). (B) SDS-PAGE gel of wt and mutant full length gelsolin
before () and after (þ) 30 min incubation with a crosslinking agent.
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addition of 1 mM IPTG for 16 h at 20 C. Cells were harvested and
resuspended in 150 ml of 20 mM sodium phosphate, 0.5 M NaCl,
10% glycerol, 20 mM imidazole, pH 7.4, supplemented with a tab-
let of protease inhibitor cocktail (cOmplete, EDTA-free, Roche)
and 10 mg/ml of Deoxyribonuclease I from bovine pancreas.
Cells were then lysed by high pressure in a Basic Z Bench top
(Constant Systems Limited, U.K.) at 25 kPSI and the crude
extract was centrifuged at 38 700 RCF for 30 min and filtered
through a 0.45 mm filter. The clarified soluble extract was loaded
onto a 1 ml HisTrap HP column (GE Healthcare Life Sciences)
and GSN variants were eluted with 20 mM sodium phosphate,
0.5 M NaCl, 10% glycerol, 0.3 M Imidazole, pH 7.4. Fractions cor-
responding to GSN were pooled and exchanged by desalting
into 20 mM Tris–HCl pH 8, 20 mM NaCl, 10% glycerol, 1 mM
EGTA, 1 mM EDTA and 1 cOmplete protease tablet.
Proteins were further purified by anion exchange chroma-
tography on a Mono Q 5/50 GL column (GE Healthcare Life
Science), eluting with a linear gradient of NaCl (20 mM to 1 M).
The peaks corresponding to pure GSN were collected and stored
in 20 mM HEPES, pH 7.4, 100 mM NaCl and 1 mM EGTA. All chro-
matographic steps were performed on a A¨KTA pure 25L (GE
healthcare).
Thermal stability
Thermal stability experiments were performed on the
Gly167Arg mutant and the full-length protein using a J-810
spectropolarimeter (JASCO Corp., Tokyo, Japan) equipped with a
Peltier system for temperature control. All measurements were
carried out in 20 mM HEPES pH 7.4, 100 mM NaCl and either
1 mM CaCl2 or 1 mM EDTA at a protein concentration of 0.2 mg/
ml. Temperature ramps were recorded from 10 to 95 C for G2
and from 20 to 95 C for GSN (slope 1 C/min) in a cuvette with a
path length of 0.1 cm and monitored at a wavelength of 218 nm.
The Tm was calculated as the maximum of the first-derivative
of the traces. Spectra before and after the unfolding ramp were
recorded (200–260 nm).
Analytic GF and MALS
All analytic GFs of G2 variants and Db1G2 were carried out using
a SuperdexTM75 Increase 10/300 GL column (GE Healthcare Life
Science). In order to follow the dimerization of the protein,
0.5 mg/ml of isolated dimer and monomer were incubated in
three different conditions:
20 mM HEPES pH 7.4, 0.3 M NaCl, 1 mM CaCl2, 4 C
20 mM HEPES pH 7.4, 0.3 M NaCl, 1 mM CaCl2, 25 C
20 mM HEPES pH 7.4, 0.3 M NaCl, 1 mM EDTA, 4 C
A total of 200 ml aliquots were collected at different time
points and loaded into the column. The area of the single peaks
was calculated as a percentage of the total area of all observed
species.
Analytic GFs for full length GSN and the variant Gly167Arg
were performed with 200 ml samples at a concentration of
0.5 mg/ml in 20 mM HEPES pH 7.4, 100 mM NaCl and either
1 mM EDTA or 1 mM CaCl2 using a Superdex
TM200 Increase 10/
300 GL (GE Healthcare Life Science).
Molar mass of monomer and oligomer present in Gly167Arg
GSN sample were characterized with a DawnVR HeleosVR Multi
Angle Light Scattering (Wyatt, Santa Barbara, CA, USA) mounted
on a GF-HPLC system. Two hundred microliters of 4 mg/ml sam-
ple were separated by GF, as previously described, connected
on-line with the DawnVR HeleosVR Multi Angle Light Scattering, an
OptilabVR T-rEX Refractive Index Detector (Wyatt) and a Waters
2487 Dual k Absorbance Detector. Molar mass at different
Figure 6. Revised mechanism of gelsolin aggregation. Schematic representation of our results integrated with the current model of AGel amyloidosis. The left side of
the diagram shows the well-known proteolytic pathway, which starts with the aberrant cleavage of full length gelsolin (GSN) by furin, a calcium-dependent protease of
the Golgi network. Once the C68 fragment is formed, it is exported to the extracellular space where matrix-metalloproteases (MMPs) further process the protein, pro-
ducing short 5 and 8 kDa peptides. In addition to this calcium-dependent pathway, we observed dimerization of the protein in the absence of calcium, owing to the
intertwining of gelsolin domain 2. These oligomers might be per se prone to amyloid aggregation or be primed by circulating short fragments produced by the other
branch in the diagram.
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volumes of elution were calculated by means of Astra software
(v. 5.3.4.18, Wyatt) using 0.185 as dn/dc value.
Dynamic light scattering
A total of 1 mg/ml solutions of monomeric Gly167Arg variant
were filtered through a 0.22 mm filter (Merck Millipore Ltd.) and
incubated in the same three different conditions used for ana-
lytical GFs. Sixty microliters of the incubation mixtures were
taken at different time intervals and the hydrodynamic radius
(RH) was measured by DLS. All measurements were carried out
at 4 C in a DynaPro instrument (Protein Solutions,
Charlottesville, VA, USA). The RH measured by DLS gave a value
which is proportional to the dimer:monomer ratio, therefore
calibration was based on the GF data and RH values of
2.060.3 nm and 3.060.3 nm used as reference for the mono-
mer and dimer, respectively.
Furin proteolysis assays
Furin cleavage assays were performed as reported in (29) at two
different temperatures, 37 and 25 C. Proteolysis was monitored
by SDS-PAGE and by analytical GF. In the latter, protein samples
(0.5 mg/ml) were analyzed as described in the previous GF sec-
tion and after 16 h incubation in the furin buffer, either in the
presence or the absence of furin protease.
Crosslinking assay
In order to assess if substitution Gly167Arg promotes higher oli-
gomeric assemblies of the full-length protein, 25 mM wt and
Gly167Arg GSN were incubated with 1 mM bis(sulsosuccinimi-
dyl)suberate (BS3, ThermoFisher) in 20 mM HEPES, pH 7.4,
100 mM NaCl, 1 mM EDTA at 20 C. After 150 incubation, the
reaction was blocked by addition of 1 M Tris–HCl pH 7.5. As a
negative control, the same reactions were performed in the
absence of BS3. Products of the crosslinking reaction were ana-
lyzed by SDS-PAGE.
Crystallization, structure solution and analysis
Vapor-diffusion crystallization experiments were carried out in a
sitting drop set-up at 20 C using an Oryx-8 nanodispenser robot
(Douglas Instruments). Using 9 mg/ml G2 Gly167Arg (in 20 mM
HEPES, 300 mM NaCl, pH 7.4, supplemented with 5 mM CaCl2)
drops of 0.4 ml were prepared with different protein/precipitant
ratios. In order to find optimal crystallization conditions, several
commercial crystal screen solutions were tested (HTTM, Hampton
Research, JCSG-plusTM, Molecular Dimensions, WizardTM, Emerald
BioSystems, MorpheusVR HT-96, Molecular Dimensions).
The best diffracting crystals grew in 0.2 M ammonium ace-
tate, 0.1 M sodium citrate pH 5.6, 30% PEG 4000. Crystals were
soaked in a cryoprotectant solution containing 20% glycerol and
flash-cooled in liquid nitrogen. X-ray diffraction data were col-
lected on the ID30B beamline (ESRF, Grenoble) at 173 C. Data
were processed and scaled using XDS (51). The Gly167Arg crys-
tal structure was solved by Molecular replacement using Phaser
(52) and the structure of the Asn184Lys variant of the G2 domain
(pdb id: 5FAF) as a search model. The structure was refined with
Phenix refine (53) and model building performed with COOT
(54). Unless otherwise stated, analysis of the structures was per-
formed with PyMol (The PyMOL Molecular Graphics System,
Version 1.8 Schro¨dinger, LLC) that was also used to prepare the
figures. Refined model and structure factors were deposited in
the protein data bank under accession code 5O2Z.
Other crystals grew in 30% PEG 3000, CHES pH 9.5, 3 mM CaCl2
and diffracted to 2.6 A˚ resolution on the ID 23-2 beamline (ESRF,
Grenoble), belonging to the P21 space group with cell dimensions
[A˚] a¼ 45.1, b¼ 39.4, c¼ 62.3 and b¼ 106. In addition to the previ-
ously mentioned software, BUSTER (version 2.10.2, Global
Phasing Ltd, Cambridge, UK) was used for refinement. The struc-
ture was partially refined to final Rwork/Rfree values of 25.5/33.6%.
MD simulations
The MD simulations were performed using the program NAMD2
(55). The coordinates of the wt gelsolin domain 2 (pdb-id 1KCQ)
from Val158 to Ala261 were modified by introducing the
Gly167Arg mutation. Using the program psfgen [part of the
namd2 package (55)], H-atoms were added and partial charges
assigned to every atom in the model. A virtual box was built
around the protein (51.2 53.165.6 A˚3) and filled with 4863
water molecules. The system charge was equilibrated adding
NaCl 0.2 M [i.e. 22 Cl (20 without Ca2þ) and 18 Naþ ions], using
the vmd package (http://www.ks.uiuc.edu/Research/vmd).
Harmonic constraints to fix protein atom positions during
energy minimization of the solvent were applied for 0.5 ns, and
the systems was then equilibrated at 310 K for an additional
0.5 ns. The two simulations were run for 80 ns, with 2 fs time
steps. During the simulations, periodic boundary conditions in
NPT ensemble, with Langevin temperature control (T¼ 300 K)
and Langevin piston Nose–Hoover method (56), were used to
maintain constant temperature and pressure, respectively. To
Van der Waals interactions, a cut-off of 12 A˚ was applied, and
switched off using a smoothing function beyond 10 A˚.
Eelectrostatic interactions were treated with the Particle Mesh
Ewald method (57), using a grid of 100 points along each dimen-
sion of the simulation box.
Supplementary Material
Supplementary Material is available at HMG online.
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